Effects of Mind–Body Exercises on Schizophrenia: A Systematic Review With Meta-Analysis

Gao Xia Wei  
*Institute of Psychology Chinese Academy of Sciences*

Lin Yang  
*Alberta Health Services*

Kellie Imm  
*Keck School of Medicine of USC*

Paul D. Loprinzi  
*University of Mississippi*

Lee Smith  
*Anglia Ruskin University*

*See next page for additional authors*

Follow this and additional works at: [https://egrove.olemiss.edu/hesrm_facpubs](https://egrove.olemiss.edu/hesrm_facpubs)

Part of the Exercise Physiology Commons, Leisure Studies Commons, Recreation Business Commons, Sports Management Commons, Sports Sciences Commons, and the Sports Studies Commons

**Recommended Citation**

Wei, G.-X., Yang, L., Imm, K., Loprinzi, P. D., Smith, L., Zhang, X., & Yu, Q. (2020). Effects of Mind–Body Exercises on Schizophrenia: A Systematic Review With Meta-Analysis. Frontiers in Psychiatry, 11, 819. [https://doi.org/10.3389/fpsyt.2020.00819](https://doi.org/10.3389/fpsyt.2020.00819)

This Article is brought to you for free and open access by the Health, Exercise Science, and Recreation Management at eGrove. It has been accepted for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.
Effects of Mind–Body Exercises on Schizophrenia: A Systematic Review With Meta-Analysis

Gao-Xia Wei1,2,3, Lin Yang4,5, Kellie Imm6, Paul D. Loprinzi7, Lee Smith8, Xiangyang Zhang1 and Qian Yu9,10*

1 Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China, 2 Key Laboratory of Behavioral Science, Institute of Psychology, Chinese Academy of Sciences, Beijing, China, 3 Department of Psychology, University of Chinese Academy of Sciences, Beijing, China, 4 Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, AB, Canada, 5 Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 6 Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 7 Department of Health, Exercise Science and Recreation Management School of Applied Sciences, The University of Mississippi, Oxford, MS, United States, 8 Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom, 9 Center for Lifestyle and Mental Health, School of Psychology, Shenzhen University, Shenzhen, China, 10 Exercise and Mental Health Laboratory, School of Psychology, Shenzhen University, Shenzhen, China

Background: Mind–body exercises (MBEs) have been widely accepted as a complementary therapy for the patients with low exercise tolerance. Currently, the number of experimental studies investigating the effect of MBEs for improving symptoms in people with schizophrenia is increasing. However, results are inconsistent.

Methods: We systematically reviewed and meta-analyzed the effects of mind–body exercises on schizophrenia. Seven electronic databases (Pubmed, Web of Science, PsycINFO, Embase, Cochrane Central Register of Controlled Trials [CENTRAL], CNKI and Wangfang) were screened through October 2019 and risks of bias of included studies were assessed in Review Manager 5.3.

Results: Meta-analysis on 13 studies with 1,159 patients showed moderately significant effects in favor of mind–body exercise intervention to improve positive symptoms (SMD = 0.31; 95% CI 0.01 to 0.60; p = 0.04), negative symptoms (SMD = 0.37; 95% CI 0.14 to 0.60; p = 0.002), and depression (SMD = 0.88; 95% CI 0.63 to 1.13; p<0.00001). Meta-regression analysis revealed that the improvement in positive symptoms was positively associated with the frequency of intervention (p = 0.04), while a marginally significant correlation was observed between the improved negative symptoms and duration of each session (p = 0.06).

Conclusions: This meta-analysis supports the therapeutic effects of MBEs to aid in the treatment of schizophrenia. Further studies need to incorporate rigorous design and large sample size to identify the optimal type and dose of mind–body exercise to inform clinical practices on MBEs’ recommendations for the management of schizophrenia symptoms.

Keywords: schizophrenia, neurological disorder, mind–body exercise, intervention, yoga
INTRODUCTION

Schizophrenia, as one of the chronic and severe mental illness, usually emerges between 16 and 30 years old, with its prevalence ranging from 0.33 to 0.75% globally (1). There are three types of symptoms that may be present in people with schizophrenia, including positive symptoms (delusions and hallucinations), negative symptoms (insufficient motivation, spontaneous reduction of speech, and social withdrawal), and cognitive symptoms (executive dysfunction, inattention, and working memory impairment) (2). These complex symptoms may also lead to a decline in social function and quality of life, a high degree of disability, and concurrent emotional diseases. It has become a public health issue because of its profound impact on family and society (3).

Since its pathology still remains elusive, treatments primarily focus on alleviating symptoms of the disease and include antipsychotic medications, psychosocial counseling, and coordinated specialty care (4). Although antipsychotic drugs can effectively improve certain positive symptoms, their beneficial effects on negative symptoms are limited (3, 5–8), and around 30% of patients are refractory to treatment (9). Moreover, antipsychotic drugs are connected with side effects including hesitation, retention, and transient leukopenia (10, 11). Prolonged use of antipsychotics may exacerbate the progression of cognitive impairment caused by schizophrenia (10, 11) and even lead to more adverse effects, which has been associated with impairments of the endocrine system (weight gain, hyperprolactinemia, and diabetes mellitus), the cardiovascular system (orthostatic hypotension), and the central nervous system (dystonia, akathisia, pseudoparkinsonism, and dyskinesia) (11). Psychosocial counseling and coordinated specialty care are typically adopted as a second line of treatment when antipsychotic medications fail to alleviate symptoms. These methods are expert-based and require a significant amount of time and cost heavily. Thus, researchers have attempted to seek low risk alternative therapies for people with schizophrenia.

Tai Chi, Yoga, and Qigong (including Baduanjin and Wuqinxi) are the three most popular mild to moderate intensity mind–body exercises (MBEs), and they have been increasingly accepted for treating patients with low exercise tolerance (12–18). MBEs are characterized by slow physical movement (stretching and relaxation of skeletal muscles) coordinated with abdominal breathing and meditative stage of mind (19, 20). These unique features have intrigued researchers and clinicians to extensively investigate the therapeutic effects of MBEs on diseases, particularly for those who are diagnosed with mental illnesses like schizophrenia (21). Indeed, the number of studies reporting beneficial effects of MBEs in schizophrenia is growing. However, findings are inconsistent: some studies showed that MBEs could be a useful add-on treatment for schizophrenia (22, 23), while others did not believe MBEs could offer more advantages over regular exercise or treatment as usual (24). Thus, a systematic review is needed to synthesize the existing literature. While there were five reviews on this topic, they focused on either one type of MBE (25), just negative symptoms (26, 27), qualitative synthesis (26) or MBEs-active control comparison (28), or included non-MBE studies (26), which make it difficult to provide an overview of MBE-induced effect on multiple symptoms of schizophrenia. Therefore, a comprehensive review with quantitative synthesis is necessary to systematically investigate the association between MBEs and a wide range of health outcomes in schizophrenia. Findings of this meta-analysis can identify knowledge gaps and provide researchers and clinicians with evidence-based recommendations so as to develop effective MBE treatments for schizophrenia patients.

METHODS

This study followed PRISMA guidelines (29) and Cochrane Collaboration’s recommendation (30) for systematic reviews and meta-analyses.

Search Strategies

Five English databases (PubMed, Web of Science, PsycINFO, Embase, Cochrane Central Register of Controlled Trials (CENTRAL)) and two Chinese databases (CNKI, Wangfang) were systematically searched from their inception to October 1st 2019. Literature search was detailed below:(((schizophrenia [Title/Abstract]) OR schizoidic [Title/Abstract]) AND ((((((mind–body [Title/Abstract]) OR mind body [Title/Abstract]) OR meditation [Title/Abstract]) OR meditative [Title/Abstract]) OR Tai Chi [Title/Abstract]) OR Taiji [Title/Abstract]) OR Qigong [Title/Abstract]) OR Baduanjin [Title/Abstract]) OR Wuqinx [Title/Abstract]) OR Yoga [Title/Abstract]) OR Yogic [Title/Abstract]) OR Pilates [Title/Abstract]). Reference lists of identified studies were also screened.

Eligibility Criteria

Firstly, studies (including randomized controlled trials and controlled trials with non-randomization) published in English and Chinese were considered eligible only if full-text articles could be retrieved. Secondly, subjects had to be aged 16 and above who were diagnosed with schizophrenia. Thirdly, to be eligible, the experimental group must involve at least one type of MBE (e.g., Tai Chi, Qigong, or Yoga) alone or a combined training mode, whereas participants in the control group maintained their unaltered lifestyle or engaged in an active control condition like psychotherapy. Initially identified records were screened by two independent reviewers to remove duplicates and obviously irrelevant records. Then, potentially eligible full-text articles were read to determine if they met the eligibility criteria or not. Disagreements were discussed with a third reviewer author.

Data Extraction and Management

Two reviewers used a priori developed data extraction forms to record all the information and extract data on patients independently in demographic data, methods, interventions, protocol as well as the outcomes.
Risk of Bias in Individual Studies
Risk of bias of eligible studies was assessed in Review Manager 5.3 software and the criteria of Cochrane Handbook for Systematic Reviews and meta-analysis were followed (30). The quality of evidences were also assessed via GRADE (Grading of Recommendations Assessment, Development and Evaluation) system (31).

Data Analysis
Assessment of Effect Size
Review Manager software was used for meta-analyses in random-effects model (30). Meta-analysis was only conducted if there were two or more pairs (experimental group vs control group) of comparisons on at least one health outcome (30). Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated as the difference in means between groups divided by the pooled standard deviation. SMD that reflects the magnitude of the overall effect size was categorized into: 1) Small = 0.2 to 0.5; 2) moderate = 0.5 to 0.8 and 3) large = 0.8 and above (32).

Levels of evidence were classified into five levels (strong evidence, moderate evidence, limited evidence, conflicting evidence, and no evidence) based on consistent findings, number of RCTs and risk of bias (33).

Assessment of Heterogeneity
I² statistic was used to identify between-study heterogeneity (low heterogeneity = 0–25%, moderate heterogeneity = 26–50%, substantial heterogeneity = 51–75%, and considerable heterogeneity = 76–100%) (30, 34).

Meta-Regression
Weighted meta-regressions were conducted for continuous, moderator variables like total duration of intervention, frequency of intervention, and duration of each session (35).

RESULTS
Literature Search
As Figure 1 showed, the literature search retrieved 308 records in total, and 118 records were excluded for duplication. Then, 190 records were screened by title and abstract, and 125 records were excluded for relevancy. Sixty-five full-text articles were screened, and 52 records were excluded with reasons (two included non-schizophrenia patients, two did not use MBEs in the experimental group, 17 did not remain unaltered lifestyle or engage in active control condition like psychotherapy in the control group, 26 without relevant outcomes, two non-controlled

FIGURE 1 | The Detailed Process of Study Selection.
experiments, two reviews and one non-original publication). Finally, 13 studies with 1,159 patients were included in this systematic review and meta-analysis (22–24, 36–45).

**Study Characteristics**

This systematic review and meta-analysis included 13 studies (11 randomized controlled studies (22–24, 36, 38–42, 44, 45), one non-randomized controlled study (37) and one quasi-experimental study (43). Characteristics of the participants, interventions, and outcome assessments are shown in Table 1.

**Setting and Participant Characteristics**

Among the 13 studies that were included, six originated from India (559 participants), three from China (376 participants), two from Japan (106 participants), one from Turkey (100 participants) and one from America (18 participants). Patients were recruited from hospitals, rehabilitation residencies, a community health center, and mental health centers.

Patients in five studies were diagnosed with schizophrenia according to DSM-IV, two with DSM-IV-TR, one with Diagnostic Interview for Genetic Studies (DIGS), and two with ICD-10. Two studies did not report the diagnostic criteria. Patients in one study were diagnosed with psychiatric disorders according to ICD-10. In the study of Bhatia et al., physical and mental comorbidities were: bipolar I disorder (n = 40), major depression disorder (n = 37) and cardiology (n = 68). Patients’ mean age ranged from 18 to 65 years. All trials included both males and female.

**Risk of Bias Within Studies**

Figure 2 summarizes the risk of bias in the selected studies. It shows that the selected studies demonstrated low risk of bias except blinding of participants and personnel for its unfeasibility for conducting MBEs’ interventional study. Specifically, 11 studies were RCTs and used adequate random sequence generation. Only one study stated that assessors were not blinded, and one study had attrition bias (incomplete outcome data). Six studies had allocation concealment procedures. Three studies had been affected by reporting bias, and four had other potential sources of bias. Additionally, according to the assessment through GRADE system, five of 10 outcomes (positive and negative symptoms, depression, general psychopathology, and social function) were of moderate quality, while the others were of low quality (Table 2).

**Outcomes**

**Mind–Body Exercises vs. Treatment as Usual**

Nine studies with data on the effects of MBEs on positive symptoms were entered into the model 1 (22–24, 36, 39–42, 45). A sensitivity analysis was performed to determine consistency of the effects of MBEs on positive symptoms. By checking both the visually asymmetrical Funnel Plot (Figure 3) and the Egger’s Regression Test (Egger’s regression intercept = 0.88, p < 0.00001), one study was then removed (SMD = −0.19) (41). After that, the remaining eight studies showed a symmetrical Funnel plot (Egger’s regression intercept = 0.88, p = 0.58). Meta-analysis showed that compared with the control group, the aggregated results showed a benefit in favor of MBEs on negative symptoms (SMD = 0.43; 95% CI 0.20 to 0.65; I² = 46%; p = 0.0002; Figure 3).

Four studies with data on the effects of MBEs on depression were entered into the model 2 (22, 24, 36, 40). Compared with the control group, the aggregated results showed a significant benefit in favor of MBEs on depression (SMD = 0.88; 95% CI 0.63 to 1.13; I² = 0%; P <0.00001; Figure 3).

Compared with usual treatment, there were moderately significant effects in favor of MBE intervention on improving anergia (p<0.0001) and side effects (p = 0.007). However, no significant effects were found on general psychopathology (p = 0.18), social function (p = 0.18), cognition (p = 0.20), quality of life (physical score: p = 0.16), (psychological score: p = 0.16), (social score: p = 0.23), (environment score: p = 0.37), and extrapyramidal symptoms (p = 0.13).

**Meta-Regression**

For both positive and negative symptoms, multiple separate meta-regressions were performed for total minutes, weekly frequency, and MBE session length. Results showed that weekly frequency was significantly correlated with improved positive symptoms (p = 0.04; Figure 4). Notably, session length was marginally correlated with improved negative symptoms (p = 0.06; Figure 4). All results of meta-regression are presented in Figure 4.

**DISCUSSION**

This meta-analysis systematically evaluated emerging evidence regarding the effects of MBEs on multiple health outcomes for individuals with schizophrenia. Results of the current review indicate that MBEs (primarily including Tai Chi and Yoga) may have beneficial effects for improving disease-specific outcomes (positive symptom, negative symptom and depression). Such promising results suggest that MBEs could be an effective complementary therapy for symptomatic management of
| Study                  | Age (mean or range) | Gender | Diagnostic; Diagnostic criteria | Setting | Intervention of control group (N) | Intervention of experimental group (N) | Cointervention | Duration of intervention | Study duration | Measurements of outcome |
|------------------------|--------------------|--------|---------------------------------|---------|----------------------------------|----------------------------------------|---------------|--------------------------|---------------|--------------------------|
| Behere et al. (13)     | 18-60              | M:F    | Schizophrenia; DSM IV           | Hospital outpatients | Treatment as usual (N = 17) | Yoga (N = 27) | Antipsychotic medication | Not mentioned | 1 month by yoga instructor | - PANSS | - SOFS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Penn CNB               |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SANS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SAPS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - GAF                    |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SOFS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - WHODAS-II              |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Shedding Rate: 33%     |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Chinese Version of the PANSS |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Forward and backward digit spans test of the Chinese Wechsler Adult Intelligence Scale |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - HDRS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SAPS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - GAF                    |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SOFS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - WHODQL-BREF            |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Shedding Rate: 2%      |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - HDRS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SAPS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - GAF                    |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - SOFS                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - WHODAS-II              |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - Shedding Rate: 20%     |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - DIEPS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - FACT-Sz                |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - EQ-5D                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - GAF                    |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - MFES                   |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - DIEPS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - TIP-Sz                 |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - WHODQL                 |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - PANSS                  |
|                        |                    |        |                                 |         |                                  |                                        |               |                          |               | - WHODQL-BREF            |

DSM, The Diagnostic and Statistical Manual of Mental Disorders; GAF, Global Assessment of Functioning scale; PANSS, Positive and Negative Syndrome Scale; Penn CNB, University of Pennsylvania Computerized Neurocognitive Battery; SANS, Scale for Assessment of Negative Symptoms; SAPS, Scale for Assessment of Positive Symptoms; SOFS, Social and Occupational Functioning Scale; AMMS, Abnormal Involuntary Movement Scale; WHODQL-BREF, World Health Organization Quality of Life-BREF; HDRS, Hamilton depression rating scale; SAS, Simpson angus scale for extrapyramidal side effects; DGS, Diagnostic Interview for Genetic Studies; CMDT, Minnesota Rate of Manipulation Test; SANs, Scale for the Assessment of Negative Symptoms; WHODAS-II, World Health Organization Disability Assessment Schedule; ICD-10, The International Classification of Diseases, 10th edition; DIEPS, The Drug Induced Extrapyramidal Symptoms Scale; FACT-Sz, The Functional Assessment for Comprehensive Treatment of Schizophrenia; EQ-SD, The EuroQol-5 Dimensions; GAF, Global Assessment of Functioning; MFES, Modified Falls Efficacy Scale in Japanese; TIP-Sz, Targeted Inventory on Problems in Schizophrenia; PROGDS, Functional Remission of General Schizophrenia Scale.
schizophrenia. More specifically, weekly frequency has shown to be positively associated with improved positive symptoms, while session length is marginally associated with negative symptoms with non-significant level. Notably, findings of this meta-analytic paper appear to be consistent with two previous reviews on negative symptoms (26, 28), but not positive symptoms.

In the early literature, MBEs are defined as mild to moderate-intensity of exercise modality where practitioners need to perform physical movement at slow pace while integrated with mental focus and relaxation, meditative state of mind, and deep abdominal breathing (46). Such nature of MBEs has been extensively investigated, suggesting that these unique exercise modalities have beneficial effects for mood regulation in healthy populations and treating disease-specific outcomes among individuals with psychiatric disorders, especially negative emotion (e.g., anxiety and depression). Therefore, it seems to be reasonable to observe improved negative symptoms of schizophrenia in this systematic review.

Prefrontal and temporal cortex abnormalities have been shown to be connected with symptoms (negative emotion, inattention, dysfunction in cognition) of schizophrenic patients (47–49). Biological mechanism remains largely unknown about how MBEs affect symptoms of schizophrenia. Some researchers proposed that these positive results may be attributed to Tai Chi-induced change in brain intrinsic cortical structure and function (50, 51). Early imaging studies by Wei et al. (50) indicated that Tai Chi training was associated with increased cortical thickness in brain regions related to executive functions (50), as well as decreased functional homogeneity in dorsolateral prefrontal cortex that potentially optimizes locally functional organization (51). Such Tai Chi-induced change in the prefrontal lobes of the elderly may be a possible explanation for the observed positive effects for symptoms of schizophrenia in the current review. Additionally, as mentioned previously, meditative stage of mind as an essential element of MBEs needs to be achieved while performing physical movement in coordination with breathing control and mental focus. Meditation alone as an intervention program has been extensively investigated, suggesting that it could positively induce cortical change in the ACC, prefrontal cortex, posterior cingulate cortex, and insula (52–57). These areas were regarded as core regions for self-regulation of attention (52, 53), emotion (54, 56), and awareness (55, 57). Thus, it is plausible that the meditative component of MBEs might play an important role to alleviate symptoms of schizophrenia by improving brain structure and function.

Glucose metabolic abnormality was highly prevalent in patients with schizophrenia. This abnormality is mainly processed by a decrease in cerebral insulin receptors’ (β-subunit) expression (58), signal transduction protein Akt1 activity (59) and insulin-degrading enzyme neuronal expression (60). Different patterns of regional glucose metabolism are related to different schizophrenia syndromes: psychomotor poverty with left prefrontal and superior parietal metabolic activity, reality distortion with left temporal lobe, and disorganization with left inferior parietal lobule (61). Recently, Huocheng et al. reported that aerobic exercise has beneficial effects for improving glucose metabolism in the medial frontal gyrus (MFG), which involves executive and visuospatial attentional functions (62). A recent study found that one-year aerobic exercise improved not only the glucose metabolism but also psychiatric symptoms (63). Thus, MBEs as typical type of aerobic exercise modalities may have the potential to improve symptoms of schizophrenia through regulating glucose metabolism.

Several limitations should be acknowledged while interpreting our findings. Firstly, several included studies had a small sample size with incomplete information, which limited our capability to conduct subgroup analyses and more comprehensive data exploration of moderators. Secondly, MBEs were offered as adjunctive treatments of existing interventions but not mono-therapy in most studies. It is difficult to determine whether the positive result is due to MBEs only, the synergistic intervention, or conventional treatment received.

Implication
This study showed that MBEs are beneficial for schizophrenia as an adjunctive treatment. These benefits can be seen in various aspects of schizophrenia prognosis and exist throughout a person’s life. In addition, MBE can also reduce the potential risks of antipsychotics (i.e., hesitation, retention, and transient
TABLE 2 | Summary of findings via GRADE System.

Mind-Body Exercises Compared with Treatment as Usual for Schizophrenia

Patient or population: patients with schizophrenia.
Settings: home, community, or hospital.
Intervention: mind-body exercises.
Comparison: treatment as usual.

| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments |
|----------|----------------------------------------|--------------------------|-----------------------------|-------------------------------|----------|
|          | Assumed risk                            | Corresponding risk        |                             |                               |          |
|          | Treatment as Usual                      | Mind-body Exercises       |                             |                               |          |
| Positive Symptoms | The mean score ranged across control groups from −0.60 to 4.50. | The mean score in the intervention groups was 2.56 (0.12 to 6.00). | / | 747 | ⊕⊕⊕⊝ | moderate |
| Negative Symptoms | The mean score ranged across control groups from −0.70 to 4.30. | The mean score in the intervention groups was 2.68 (0.70 to 7.71). | / | 747 | ⊕⊕⊕⊝ | moderate |
| General Psychopathology | The mean score ranged across control groups from −1.75 to 2.70. | The mean score in the intervention groups was 3.71 (−0.60 to 13.30). | / | 456 | ⊕⊕⊝ | moderate |
| Quality of Life (Physical Score) | The mean score ranged across control groups from −8.25 to 2.50. | The mean score in the intervention groups was 7.91 (−0.42 to 12.25). | / | 323 | ⊕⊕⊝ | low |
| Quality of Life (Psychological Score) | The mean score ranged across control groups from −8.63 to 4.38. | The mean score in the intervention groups was 13.22 (2.08 to 22.5). | / | 323 | ⊕⊕⊝ | low |
| Quality of Life (Social Score) | The mean score ranged across control groups from −8.13 to 8.63. | The mean score in the intervention groups was 12.76 (−0.09 to 23.10). | / | 323 | ⊕⊕⊝ | low |
| Quality of Life (Environment Score) | The mean score ranged across control groups from −5.00 to 0.25. | The mean score in the intervention groups was 4.82 (0.18 to 10.57). | / | 289 | ⊕⊕⊕ | moderate |
| Social Function | The mean score ranged across control groups from −1.48 to 3.54. | The mean score in the intervention groups was 4.85 (2.74 to 7.57). | / | 132 | ⊕⊕⊝ | low |
| Cognition | The mean score ranged across control groups from −0.07 to 1.40. | The mean score in the intervention groups was 1.39 (1.07 to 1.77). | / | 132 | ⊕⊕⊝ | low |
| Depression | The mean score ranged across control groups from −1.63 to 2.33. | The mean score in the intervention groups was 2.71 (0.70 to 4.83). | / | 269 | ⊕⊕⊕ | moderate |
| Anemia | The mean score ranged across control groups from −2.00 to 1.03. | The mean score in the intervention groups was 2.34 (1.13 to 3.20). | / | 109 | ⊕⊕⊝ | low |
| Side Effects | The mean score ranged across control groups from −0.02 to 0.10. | The mean score in the intervention groups was 0.60 (0.30 to 0.90). | / | 149 | ⊕⊕⊝ | low |
| Extrapyramidal Symptoms | The mean score ranged across control groups from 0.80 to 0.80. | The mean score in the intervention groups was 0.20 (−0.10 to 0.50). | / | 106 | ⊕⊕⊝ | low |

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI, Confidence Interval; RR, Risk Ratio; GRADE, Grading of Recommendations Assessment, Development and Evaluation.

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

leukopenia) (10, 11), which are critical to the patients’ quality of life and well-being. Therefore, a comprehensive intervention of pharmacological and non-pharmacological treatment (i.e., MBE) should be considered for patients with schizophrenia. In addition, it is necessary for the therapists who teach MBEs to receive training in mental health disorders to sensitize them to the needs of patients. Psychiatrist should work closely with therapists so that they can meet the needs of patients at any time.
FIGURE 3 | Forest Plot and Funnel Plot for Positive Symptoms, Negative Symptoms, and Depression.

FIGURE 4 | Meta-Regression of Intervention Factors for Improving Symptoms.
CONCLUSIONS

This meta-analytic review of the existing literature suggests that MBEs are effective interventions to improve symptoms of schizophrenia. These findings provide safe and accessible therapy to existing mainstream treatment (antipsychotic drugs and psychotherapy), and clinicians should consider using MBEs as complementary treatment for schizophrenia.

In the future, more strictly-designed RCTs with larger scale are warranted to examine the therapeutic effects and potential mechanism of MBEs for schizophrenia. Additionally, it is also needed to explore how other types of MBEs (i.e., Tai Chi Chuan, Qigong) influence the symptoms of schizophrenia so as to advance the understanding of general benefits of the varied forms of MBEs. Since impaired cognition is one of the main symptoms for schizophrenia, researchers should investigate the effect of MBEs on cognitive improvement of schizophrenia.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding author.

REFERENCES

1. Moreno-Küstner R, Martin C, Pastor L. Prevalence of psychiatric disorders and its association with methodological issues. A systematic review and meta-analyses. PloS One (2018) 13(4):e0195687. doi: 10.1371/journal.pone.0195687
2. van Os J KS. Schizophrenia. Lancet (2009); (9690) 374:635–45. doi: 10.1016/ s0140-6736(09)60995-8
3. Dominguez Mde G, Viechtbauer W, Simons CJ, van Os J, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull (2009) 135(1):157–71. doi: 10.1037/a0014415
4. Hadjulis M, Margariti M, Lazaridou M, Angelidis GF, Fotopoulos V, Markaki L, et al. Clinical guidelines for the management of schizophrenia: Pharmacological and psychological intervention ions (III). Psychiatrki (2018) 29(4):303–15. doi: 10.22365/psychy.2018.294.303
5. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med (2006) 36(11):1535–40. doi: 10.1017/s0033291706008191
6. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand (2007) 115(1):4–11. doi: 10.1111/j.1600-0447.2006.00947.x
7. Pålkanen A, Hatonen M, Kuosmanen L, Valimaki M. Individual quality of life of people with severe mental disorders. J Psychiatr Ment Health Nurs (2009) 16(1):3–9. doi: 10.1111/j.1365-2850.2008.01308.x
8. Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev (2012) 21(1):9. doi: 10.1186/2191-1991-2-9
9. Sheitman BR, Lieberman JA, Kaplan RD, Szychtmann H, Franco S, Szychtmann B, et al. The natural history and pathophysiology of treatment resistant schizophrenia. Schizophr Res (1998) 32(3–4):143–50. doi: 10.1016/0920-9964(98)90037-7
10. Gaebel W, Stricker J, Riebebeck M. The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. Schizophr Res (2019) S0920–9964(19)30484–0. doi: 10.5414/ CP203704
11. Yasui-Furukori N, Shimoda K. Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia. (2020). doi: 10.1002/npr2.12127
12. Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand (2004) 110(4):299–305. doi: 10.1111/j.1600-0447.2004.00372.x
13. Vancampfort DKJ, De Hert M, Wv R, Seppe D, Katrien M, Joseph P, et al. Cardiometabolic effects of physical activity interventions for people with schizophrenia. Acta Psychiatr Scand (2008) 143(3):388–98. doi: 10.1111/j.1600-0447.2007.01032.x
14. Gorczynski P FG. Exercise therapy for schizophrenia. Cochrane Database Syst Rev (2010) 5:CD004412. doi: 10.1002/14651858.CD004412.pub2
15. Vancampfort D, Knapen J, Probst M, Van Winkel R, Peuskens J, Maurissen K, et al. The therapeutic value of physical exercise for people with schizophrenia. Lancet (London England) (2010) 52(8):565–74. doi: 10.1016/s0140-6736(09)60995-8
16. Holley J, Cronde D, Tyson P, Lovell G. The effects of physical activity on psychological well-being for those with schizophrenia: A systematic review. Br J Clin Psychol (2011) 50(1):84–105. doi: 10.1348/014466510x496220
17. Vancampfort D, Knappen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand (2012) 125(5):352–62. doi: 10.1111/j.1600-0447.2011.01814.x
18. Zou L YA, Li C, Wei GX, Chen KW, Kinser PA. Effects of meditative movements on major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. J Clin Med (2018) 7(8):195. doi: 10.3390/jcm7080195
19. Wu WW, Kwong E, Lan XY, Jiang XY. The Effect of a Meditative Movement Intervention on Quality of Sleep in the Elderly: A Systematic Review and Meta-Analysis. J Altern Complement Med (New York NY) (2015) 21(9):509–19. doi: 10.1089/acm.2014.0251
20. Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: A descriptive review. Brain Behav Immun (2016) 51:1–11. doi: 10.1016/j.bbi.2015.06.012
21. Chen S, Zhang Y, Wang YT, Liu XL. Traditional Chinese Mind and Body Exercises for Promoting Balance Ability of Old Adults: A Systematic Review.
59. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. *Schizophr Res* (2006) 84(1):1–14. doi: 10.1016/j.schres.2005.11.009

60. Ronald K HS SF. Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by position emission tomography (PET). *Schizophr Res* (1993) 11(1):47–54. doi: 10.1016/0920-9964(93)90037-J

61. Liao HC, Zhong SG, Li P, Chen WB, Cheng C, Wang YG, et al. Effects and mechanism of moderate aerobic exercise on impaired fasting glucose improvement. *Lipids Health Dis* (2015) 14:157. doi: 10.1186/s12944-015-0117-z

62. Porto FH, Coutinho AM, Pinto AL, Gualano B, Duran FL, Prando S, et al. Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. *J Alzheimer's Dis JAD* (2015) 46(3):747–60. doi: 10.3233/jad-150033

63. Nyboe L, Vestergaard CH, Moeller MK, Lund H, Videbech P. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up. *Schizophr Res* (2015) 168(1-2):381–7. doi: 10.1016/j.schres.2015.07.053

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Wei, Yang, Imm, Loprinzi, Smith, Zhang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*